eTheRNA is on track to move the mRNA production unit from Jette to Niel in 2017 and to triple its capacity
Brussels (Belgium), 4 August 2016 — eTheRNA immunotherapies NV, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has strengthened its management team with the appointment of Alain Deloof (foto) as Production Lead , effective August 1, 2016.
In the past six years Alain Deloof held various management functions at Janssen Diagnostics, of which the last four years as Senior Site Integrator. In that function he was responsible for the resource management of the organization’s European labs. He was also actively involved in reproducibility studies set up in the framework of the cooperation between Janssen Pharmaceutica and Biocartis with the aim to jointly develop analyses for Biocartis’ molecular diagnostic system. Alain Deloof joined the Janssen Diagnostics organization following the acquisition of Tibotec-Virco by Johnson & Johnson. Being a scientist at Tibotec-Virco for twelve years, he also built a strong expertise in the field of viral RNA extraction. Prior to his career at Tibotec-Virco, Alain Deloof performed laboratory work at the Diabetic Research Center of the Vrije Universiteit Brussel (VUB).
Dirk Reyn, CEO eTheRNA: "We warmly welcome Alain to our team. Alain has built a wide know-how and expertise in the production of mRNA constructs. Besides the development of our proprietary mRNA-based immunotherapies, the production of mRNA for third parties represents another pillar of our strategy. This summer, the construction and refurbishing works for the mRNA production lab in Niel, near Boom (Belgium), will be finished. According to our expectations, the first test and verification batches will be manufactured here in accordance with the international Good Manufacturing Practices (GMP) this autumn, anticipating the official recognition of the mRNA production lab by the Belgian federal agency for pharmaceuticals and health products (FAGG), which we hope to obtain early 2017."
Alain Deloof, Production Lead eTheRNA: "It is a great challenge to meet this schedule, but I am highly motivated to make it. With the new lab we have the appropriate tools to guarantee the support for our own products during the major part of their clinical development. The additional income that stems from the mRNA production for third parties, will be reinvested in our proprietary research."
Since the EUR 24 million financing round that was successfully completed in March of this year, eTheRNA’s staff has almost doubled. The company now has 16 employees and expects this number to grow further in the coming months.